Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7924961 | 0.78 | CYP1A2 (0.42) | HSD17B10PIK3CBDYRK1AMAPTKDM4E | |
| SCHEMBL23346665 | 0.77 | PIK3CB (0.49) | HSD17B10PIK3CBDYRK1AEGFRMAPT | |
| SCHEMBL19630106 | 0.77 | PIK3CB (0.41) | PIK3CBGRIN2BGRIN1 | |
| SCHEMBL2573248 | 0.77 | HSD17B10 (0.37) | HSD17B10DYRK1AKDM4EHTTALDH1A1 | |
| SCHEMBL2579990 | 0.77 | HSD17B10 (0.37) | HSD17B10DYRK1AKDM4EHTTALDH1A1 | |
| SCHEMBL19152184 | 0.77 | HPGD (0.44) | HSD17B10PIK3CBMAPTKDM4EHTT | |
| SCHEMBL12291376 | 0.77 | GRIN2B (0.40) | HSD17B10GRIN2BGRIN1 | |
| SCHEMBL22155718 | 0.76 | PIK3CB (0.40) | HSD17B10PIK3CBDYRK1AMAPTKDM4E | |
| SCHEMBL23555720 | 0.75 | BRD9 (0.48) | HSD17B10KDM4EHTTALDH1A1BRD9 | |
| SCHEMBL23125736 | 0.74 | HSD17B10 (0.35) | HSD17B10DYRK1AHTTMETKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082069-A1 | COMPOUND BINDING TO CRBN PROTEIN AND DEGRADATION AGENT OF PROTEIN | 中国海洋大学 | 2025-04-24 | — | — | WO | disclosed |
| CN-119841843-A | Compound combined with CRBN protein and degradation agent of CRBN protein | 中国海洋大学 | 2025-04-18 | — | — | CN | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| EP-3268373-B1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3268373-B1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-10-07 | — | — | US | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| US-20140343033-A1 | AZAINDOLE DERIVATIVES | Takeda Califomia, Inc. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8835420-B2 | Azaindole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-16 | — | — | US | disclosed |
| US-8835420-B2 | Azaindole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-16 | — | — | US | disclosed |
| US-8835420-B2 | Azaindole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-16 | — | — | US | disclosed |
| WO-2014011568-A1 | AZAINDOLE DERIVATIVES WHICH ACT AS PI3K INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-16 | — | — | WO | disclosed |
| US-20140018344-A1 | AZAINDOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
| US-20140018344-A1 | AZAINDOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
| US-20140018344-A1 | AZAINDOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-16 | — | — | US | disclosed |
| WO-2011110575-A1 | DERIVATIVES OF 2-[2-(BENZO- OR PYRIDO-) THIAZOLYLAMINO]-6-AMINOPYRIDINE, USEFUL IN THE TREATMENT OF RESPIRATORIC, ALLERGIC OR INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011110575-A1 | DERIVATIVES OF 2-[2-(BENZO- OR PYRIDO-) THIAZOLYLAMINO]-6-AMINOPYRIDINE, USEFUL IN THE TREATMENT OF RESPIRATORIC, ALLERGIC OR INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343033-A1 | AZAINDOLE DERIVATIVES | PIK3R5, PIK3R1, PIK3R2 | HSD17B10 2437/4885PIK3CB 13/4885DYRK1A 1604/4885 |
| US-20210309614-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS1, ADAMTS5, ADAMTS7 | HSD17B10 2303/4885PIK3CB 1150/4885DYRK1A 2071/4885 |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | HSD17B10 2303/4885PIK3CB 1150/4885DYRK1A 2071/4885 |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | HSD17B10 1479/4885PIK3CB 3676/4885DYRK1A 2316/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | HSD17B10 1479/4885PIK3CB 3676/4885DYRK1A 2316/4885 |
| US-20140018344-A1 | AZAINDOLE DERIVATIVES | PIK3R5, PIK3R1, PIK3R2 | HSD17B10 2437/4885PIK3CB 13/4885DYRK1A 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.